Presenting at AHS 2022, researchers assessed the efficacy of galcanezumab 120 mg/month in the prevention of episodic migraine.
All articles by Maria Arini Lopez, PT, DPT, CSCS, CMTPT
Presenting at AHS 2022, researchers determined the effect of generalized anxiety disorder on the responsiveness of BoNT-A treatment from pediatric patients with chronic migraine.
Presenting at AHS 2022, researchers assessed the effect of a high-fat meal on the pharmacokinetics of immediate release atogepant tablets.
Presenting at AHS 2022, researchers evaluated the real-world effectiveness of ubrogepant in combination with onabotulinumtoxinA to treat breakthrough migraine.
Researchers evaluated the safety and efficacy of neuromuscular electric stimulation therapy in the reduction of knee osteoarthritis-related pain, stiffness, and function.